We would like to thank our shareholders for their continued support.

During the interim consolidated accounting period, in Japan, sales of Closed Drug Mixing/Infusion Systems, which we are focusing on as a core business, were strong, and sales of Prefilled Syringes, for which drug prices were raised in the NHI drug price and medical service fee revisions, and Dysphagia-related products, for which medical service fees were applied, increased. In overseas markets, sales of our mainstay Apheresis Kits and Blood Bags increased, and sales of AV Fistula Needles (AV Fistula Needles for hemodialysis) also remained strong. In addition, sales of Leukocyte Reduction Filters, which we acquired in the previous fiscal year, increased.

As a result of the above, net sales of 33,830 million yen, up by 8.3% / 2,582 million yen (year-over-year), due in part to the increase in yen-denominated sales resulting from the depreciation of the yen. Despite the effect of sales increase and the price pass-on measures that have been implemented since the previous period, Operating profit was 155 million yen (operating loss of 320 million yen in the previous interim consolidated accounting period) due to the increase in depreciation expenses associated with capital investment, in addition to the soaring costs of raw materials and electricity. Despite the fact that there was an investment profit from the equity method, the exchange rate worked against us to a large extent, and as a result of recording an exchange loss, the ordinary loss was 118 million yen (ordinary loss of 135 million yen in the previous interim consolidated accounting period). After adding and subtracting corporate taxes, etc., the interim net loss attributable to the parent company was 258 million yen (the interim net loss attributable to the parent company for the previous interim consolidated accounting period was 258 million yen).

In accordance with our basic policy on profit distribution, we have decided to pay a dividend of 8.5 yen per share.

As a bridge between people and medicine, JMS will continue to create and provide "value" in the medical field in each country and region, and contribute to improving the quality of medical care and people's lives worldwide, while enhancing corporate value through sound business activities.

We would like to ask our shareholders for their continued support and cooperation.

December 2024